Lv31
368 积分 2024-09-24 加入
Skeletal muscle loss and sarcopenia in obesity pharmacotherapy
2小时前
已完结
The effect of obesity pharmacotherapy on body composition, including muscle mass
3小时前
已完结
After obesity drugs’ success, companies rush to preserve skeletal muscle
3小时前
已完结
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
14天前
已完结
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
21天前
已完结
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
21天前
已完结
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
23天前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
24天前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
24天前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
24天前
已完结
皖公网安备34019202002308
